Cancer Med:深圳先进院等成功构建23个中国妇女早期宫颈癌抗原树

2017-03-14 佚名 中国科学报

鸡年伊始,中国科学院深圳先进技术研究院陈志英团队与华大基因等合作的一项癌症研究成果发表在美国Cancer Medicine 杂志上。

鸡年伊始,中国科学院深圳先进技术研究院陈志英团队与华大基因等合作的一项癌症研究成果发表在美国Cancer Medicine 杂志 上。这个合作项目是开发电子计算机算法,利用癌症基因组学,构建23个中国妇女早期宫颈癌的 “癌症抗原树”,目的是帮助找出最佳癌症免疫治疗靶点,以提高疗效。

科学家利用人类基因不断突变、突变可以遗传到后代两大特点,做出人类起源于非洲的结论,并绘制出了走出非洲衍化出不同人种的路线图。除了肤色不同,人类种族间对疾病与治疗的敏感性都有差异。同样,癌症起源于一个细胞,是基因突变积累的结果,这些突变产生很多新靶点,成为癌细胞独有且理想的治疗靶点,不会伤及正常细胞。由于突变不断发生,衍生出许多细胞群,不同细胞群有不同的靶点组合,对治疗的反应也不同。目前的免疫治疗技术,大多只针对部分细胞群,对于实体瘤来说,临床上可使肿瘤缩小、病情稳定,但残留癌细胞群继续生长,不久又复发。

“癌症抗原树”是团队开发的新电子计算机算法,根据癌症基因组学的资料,找出一个癌症内所有细胞群及其靶点之间的进化关系, 帮助确定“树干”上所有癌细胞共有的靶点,大大提高治疗疗效。该算法对指导发展新一代癌症免疫治疗技术有重要指导意义。该项目是团队构建中的“微环DNA基因载体癌症免疫治疗技术平台”的一个组成部分,旨在开发出安全、高效、方便、可负担的抗癌基因药。

图5,癌症免疫抗原树。
A. 人类走出非洲并衍化出不同种族的路线图;
B. “癌症抗原树”描绘肿瘤细胞群及其携带的肿瘤抗原的相互关系;
C. “癌症抗原树”帮助找出“树干”上的靶点,像砍树干把树砍死一样,高效治疗肿瘤;
D. 三个代表性宫颈癌抗原树。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1408021, encodeId=098f140802191, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607301, encodeId=378f160e30165, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623233, encodeId=3adc162323393, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=)]
    2017-03-16 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1408021, encodeId=098f140802191, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607301, encodeId=378f160e30165, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623233, encodeId=3adc162323393, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1408021, encodeId=098f140802191, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607301, encodeId=378f160e30165, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623233, encodeId=3adc162323393, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Mar 16 12:53:00 CST 2017, time=2017-03-16, status=1, ipAttribution=)]